Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS
Marcos de Lima(The Ohio State University), Börje S. Andersson(The University of Texas MD Anderson Cancer Center), Richard E. Champlin(The University of Texas MD Anderson Cancer Center), Elizabeth J. Shpall(Scripps MD Anderson Cancer Center), Daniel R. Couriel(The University of Texas MD Anderson Cancer Center), Sergio Giralt(Memorial Sloan Kettering Cancer Center), Munir Shahjahan(The University of Texas MD Anderson Cancer Center), Timothy Madden(The University of Texas MD Anderson Cancer Center), Xuemei Wang(The University of Texas MD Anderson Cancer Center), James A. Russell(The University of Texas MD Anderson Cancer Center), Roy B. Jones(The University of Texas MD Anderson Cancer Center), Peter F. Thall(The University of Texas MD Anderson Cancer Center), Martin Körbling(The University of Texas MD Anderson Cancer Center), Betty Pierre(The University of Texas MD Anderson Cancer Center)
Cited by 422
Related Papers
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k
CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
|British Journal of Haematology|1998|1.5k
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
|Journal of Clinical Oncology|1997|1.3k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.1k